|
Orthologous residues
|
|
TrkB (human): Y706‑p, TrkB iso4 (human): Y722‑p, TrkB (mouse): Y705‑p, TrkB iso2 (mouse): ‑, TrkB (rat): Y705‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
immunoprecipitation, phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
'neuron, cerebral cortical'-brain
|
|
Cellular systems studied:
primary cultured cells
|
|
Species studied:
rat
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
TrkB (rat)
|
pharmacological activator of upstream enzyme, mutation in upstream enzyme recognition motif
|
|
|
|
Comments:
autophosphorylation
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
BDNF
|
|
|
|
increase
|
|
|
SMI11293
|
BDNF
|
|
|
inhibit treatment-induced increase
|
|
|
CGP76030
|
BDNF
|
|
|
inhibit treatment-induced increase
|
|
|
Zn(2+)
|
|
|
|
increase
|
|
|
SMI11293
|
Zn(2+)
|
|
|
inhibit treatment-induced increase
|
|
|
CGP76030
|
Zn(2+)
|
|
|
inhibit treatment-induced increase
|
|
|
BDNF
|
|
|
|
increase
|
|
|
K252a
|
BDNF
|
|
|
inhibit treatment-induced increase
|
slight inhibition
|
|
Zn(2+)
|
|
|
|
increase
|
|
|
K252a
|
Zn(2+)
|
|
|
no effect upon treatment-induced increase
|
|
|
K252a
|
|
|
|
no change compared to control
|
|
|
|
|
Src (rat)
|
|
increase
|
inactive Src decreases
|
|
Zn(2+)
|
|
|
|
increase
|
|
|
PP1
|
Zn(2+)
|
|
|
inhibit treatment-induced increase
|
|
|
PP2
|
Zn(2+)
|
|
|
inhibit treatment-induced increase
|
|
|
PP3
|
Zn(2+)
|
|
|
no effect upon treatment-induced increase
|
|
|